VCYT FY 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$446M+23.5% YoY

Gross Profit

$298M66.9% margin

Operating Income

$16M3.6% margin

Net Income

$24M5.4% margin

EPS (Diluted)

$0.31

Cash Flow

Operating Cash Flow

$75M

Free Cash Flow

$64M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$124M

Stockholders' Equity

$1.2B

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$446M	$361M	+23.5%
Gross Profit	$298M	$248M	+20.1%
Operating Income	$16M	-$86M	+118.8%
Net Income	$24M	-$74M	+132.4%